As the founder of Chen Translational Research Consulting, I bring over 15 years of rich experience in the realm of Molecular Imaging, Nanotechnology and Oncology Drug Development.

· Key Contributor in Innovative Tumor-Targeted IND drug ELU001: Played a pivotal role in ELU001 (anti-human folate receptor alpha nanoparticle-drug conjugates) development, from lead candidates screening, preclinical MTD/efficacy studies, to GLP toxicology, CMC development, and successful IND application. Demonstrating a proven track record in advancing novel drug delivery systems from bench to bedside.

· Molecular Imaging and Nano/Biotechnology: Over 15 years of hands-on experience, demonstrating a deep understanding of molecular imaging and cutting-edge advancements in nano/biotechnology.

· Radiolabeling and Preclinical Nuclear Imaging/Therapy: Expertise in utilizing a spectrum of radioisotopes (Zr-89, Cu-64, As-72, Ge-69, Ti-45, Lu-177, Ac-225) for precise radiolabeling, enhancing preclinical nuclear imaging and therapeutic applications.

· Research Paper and Grant Writing: Extensive experience crafting impactful research papers and successful grant applications, showcasing a strong ability to communicate scientific findings effectively.

· Strategic Cross-Functional and CRO Collaboration: Adept at seamlessly working within cross-functional teams, fostering collaboration and synergy for efficient project goal achievement. Demonstrated success in collaborating with Contract Research Organizations (CROs), ensuring streamlined processes and optimal outcomes in research projects.

· Operation of Molecular Imaging Systems: Proficient in the operation of advanced molecular imaging systems, including Siemens Inveon PET/CT scanner, Focus 120 Micro-PET, IVIS Spectrum, and others, ensuring precise and reliable imaging results.